Elevance Health Q3 2026 net income rises 13% year over year to $1.34 billion
Bitget2026/10/21 10:04- Elevance Health’s third-quarter 2026 diluted earnings rose 18% year over year to $6.27 per share.
- Operating revenue increased year over year to $50.44 billion, supported by higher premium yields, CarelonRx product revenue and service fees.
- Health Benefits operating gain fell 27% year over year to $436 million, reflecting targeted investments supporting its long-term operating model.
- The full-year 2026 outlook calls for diluted earnings of at least $22 per share.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks
Goldman Sachs stated that the Japanese yen has become a better tool for hedging against AI shocks, with policy shifts reducing the risk of depreciation. The bank recommends shorting USD/JPY and EUR/JPY.


Trump promotes the "manufacturing card" again for midterm elections: Audi to invest $4 billion in a U.S. plant, plans annual production of 200,000 SUVs
Audi plans to invest 4 billion dollars to build a factory in the United States, with an annual production capacity of 200,000 SUVs, creating 4,500 jobs. The German labor union criticized the CEO's supportive attitude as "puzzling," and the final decision will be made by the Volkswagen supervisory board.

Price increases haven't suppressed demand! JPMorgan weekly tracker: Apple (AAPL.US) iPhone 18 Pro delivery cycle matches last year; Duo still out of stock for three months
A tracking report by JPMorgan shows that the delivery period for the iPhone Duo continues to be around three months, and it is unavailable for in-store pickup in all monitored regions. Meanwhile, the delivery periods for the iPhone 18 Pro and Pro Max are steadily returning to normal, with the global average delivery period having reverted to the same level as the same period last year.
